ClinicalTrials.gg
TerminatedNCT03302247Updated Oct 28, 2020Results posted

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

A Phase 2 interventional study of Nivolumab and Nivolumab+Gemcitabine in Non Small Cell Lung Cancer Stage IIIB, sponsored by Fox Chase Cancer Center. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-28.

Sponsored by Fox Chase Cancer Center · Phase 2, Interventional, and Treatment

Why this study was terminated
Unable to accrue subjects

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
110th of 120
3 · median 66
Started
2018
with 14 others
Phase 2
66 of 120
16 open now
Registered
53rd of 120
by date
Lead sponsor
2 of 120
Fox Chase Cancer Center

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 110th largest by enrollment, is one of 15 that started in 2018, is one of 66 in phase 2, and was the 53rd registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation due to development of tolerance or immunosuppression. This trial combines one drug from each category, immunotherapeutic Nivolumab and chemotherapeutic gemcitabine as it was reported that gemcitabine reduces immunosuppression by killing myeloid derived suppressor cells, thereby increasing the efficacy of Nivolumab.

Read the detailed description

Primary Objective

  • The primary objective of this proposal is to evaluate gemcitabine as a method of MDSC depletion.

Secondary Objectives

  • Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number.
  • Determine the tolerability and clinical activity (including response rate and survival) of this approach.
  • Correlate MDSC number with tumor PD-L1 expression
03

Conditions studied

  • Non Small Cell Lung Cancer Stage IIIB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of non-small cell lung cancer (NSCLC). Patients should have stage IV disease (AJCC 7th edition), stage IIIb disease that is not amenable to potentially curative treatment (e.g. chemoradiotherapy) or unequivocal progression in a prior irradiated field. Measurable or evaluable disease is required.
  2. Fresh/ archived tumor tissue available for molecular marker testing is required for entry. A tumor block or at least 5 unstained slides must be available. As an alternative FFPE cell block that is sufficient for histologic analysis is acceptable. If a patient has had status previously determined with and FDA approved assay, they have met this requirement. Tissue is still requested (but not required) for further analysis
  3. Age > 18 years.
  4. performance status 0 or 1
  5. Patients must have normal organ and marrow functions as defined below:

    White blood cells (WBC) >2,000/mcL; >100,000/mcL; ≥9g/dl; (ANC) >1,500/mcL; Serum creatinine ≤1.5 x , or

    (CrCl) ≥50 ml/min (if using Cockcroft Gault formula below):

    Female CrCl= ((140 - age in years)/(72 x serum creatinine in mg/dL)) x weight in kg x 0.85; Male CrCl= ((140 - age in years)/(72 x serum creatinine in mg/dL) x weight in kg x 1.0; /SGOT ≤ 3 x ULN

    Total :

    If no known liver : total bilirubin ≤ 1.5 x institutional upper limit (ULN) (except, subjects with Gilbert Syndrome who may have total bilirubin \< 3.0 mg/dl; If known metastasis: total bilirubin ≤ 5 ULN

  6. Negative serum pregnancy test result in Women os Child -bearing Potential ()
  7. Prior therapies:

    • Patients without activating mutations and gene rearrangements should have received at least one prior chemotherapy regimen. Any number of prior therapies is allowed except for immunotherapy (e.g. anti PD-1, PD-L1, vaccines, CTLA-4 etc.),
    • Patients with activating mutations with known documented benefit from tyrosine kinase inhibitors should have received and demonstrated progression with that inhibitor (e.g. EGFR del 19 mutation should have been treated with gefitinib, erlotinib or afatanib etc). ALK rearrangements should have been treated with an ALK inhibitor. Patients who have progressed on these agents should be assessed, if appropriate, for resistance mutations susceptible to approved agents and treated with that agent.
    • No prior gemcitabine treatment
  8. Ability to understand and willingness to sign a written and HIPAA consent document

Exclusion criteria

Exclusion Criteria:

  1. Patients with active, known or suspected disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
  2. Patients requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type reaction caused by contact allergen) is permitted.
  3. As there is a potential for hepatic toxicity with nivolumab, drugs with predisposition to hepatotoxicity should be used with caution in patients treated with nivolumab-containing regimen.
  4. Patients are excluded if they have active or . Subjects with brain metastases are eligible if have been treated without clinical or radiologic evidence of progression for 14 days prior to initiation of treatment. An MRI within 14 days of commencing therapy is required for patients with a history of brain metastases.
  5. There must be no requirement for immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.
  6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.
  7. Uncontrolled inter-current illness that would increase the risk of toxicity or limit compliance with study requirements. This includes but is not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situations that would limit compliance with study requirements.
  8. Known -positive patients on combination antiretroviral therapy are ineligible because of the abnormal immune response that results from HIV disease.
  9. Patients should be excluded if they are positive test for virus surface antigen (HBV sAg) or virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
  10. Patients who have had systemic (IV) cytotoxic chemotherapy or any other agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. If a patient received an oral agent, treatment on study can not commence at least five half-lives of the agent have elapsed.
  11. Subjects with previous (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
  12. Other active malignancy requiring concurrent intervention.
  13. Subjects with any history of interstitial lung disease.
  14. Pregnant or breast feeding.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Nivolumab+Gemcitabine

    Nivolumab infusion on day 1 and 15 with the addition of gencitabine on day 1, 8 and 15 of 28 day cycle

    Biological: Nivolumab · Drug: Nivolumab+Gemcitabine

Interventions

  • BiologicalNivolumab

    Monoclonal antibody against non small cell lung cancer

  • DrugNivolumab+Gemcitabine

    Drug pages: Nivolumab · Gemcitabine

    Gemcitabine is added to the Nivolumab treatment

06

What researchers measure

Primary outcomes

  1. Decrease in Macrophage Derived Suppressor Cells (MDSC) Numbers as a Result of Treatment With Gemcitabine.

    Immunosuppression in terms of number of circulating MDSC in the blood by comparing within each arm reduction in the number of MDSCs after each cycle of treatment

    Time frame: 2 years

Secondary outcomes

  1. Increase in T-cell Activity

    Evaluate if MDSC elimination by gemcitabine results in increase in T-cell activity

    Time frame: 2 years

07

Results

Posted Oct 28, 2020

Participant flow

Participant flow — Overall Study
MilestoneNivolumab+Gemcitabine
Started3
Completed0
Not completed3
Withdrew: The study has closed prematurely2
Withdrew: Death1

Outcome measures

PrimaryDecrease in Macrophage Derived Suppressor Cells (MDSC) Numbers as a Result of Treatment With Gemcitabine.

Immunosuppression in terms of number of circulating MDSC in the blood by comparing within each arm reduction in the number of MDSCs after each cycle of treatment

Time frame:
2 years

No measurements were reported for this outcome.

SecondaryIncrease in T-cell Activity

Evaluate if MDSC elimination by gemcitabine results in increase in T-cell activity

Time frame:
2 years

No measurements were reported for this outcome.

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab+Gemcitabine1/3 (33.3%)3/3 (100%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventNivolumab+Gemcitabine
RhabdomyolysisMusculoskeletal and connective tissue disorders1/3
Elevated CPKInvestigations1/3
MyalgiaMusculoskeletal and connective tissue disorders1/3
Intractable leg painGeneral disorders1/3
Intractable right hip painGeneral disorders1/3
Intractable lower back painGeneral disorders1/3
Most frequent other events
Showing 10 of 45
Most frequent other events
EventNivolumab+Gemcitabine
AnemiaBlood and lymphatic system disorders3/3
ConstipationGastrointestinal disorders3/3
FatigueGeneral disorders3/3
Aspartate aminotransferase increasedInvestigations3/3
Platelet count decreasedInvestigations3/3
HypoalbuminemiaMetabolism and nutrition disorders3/3
HypocalcemiaMetabolism and nutrition disorders3/3
DyspneaRespiratory, thoracic and mediastinal disorders3/3
NauseaGastrointestinal disorders2/3
ChillsGeneral disorders2/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nivolumab+Gemcitabine
<=18 years0
Between 18 and 65 years2
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab+Gemcitabine
Female1
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab+Gemcitabine
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab+Gemcitabine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White2
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Nivolumab+Gemcitabine
United States3
08

Study locations

1 site
  • Fox Chase Cancer Center - Philadelphia
    Philadelphia, Pennsylvania 19111-2497, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Mar 2019, 14 months.

Results were first posted in Oct 2020, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2017
First posted
Oct 5, 2017
StartActual
Jan 15, 2018
Primary completionActual
Mar 21, 2019
CompletionActual
Jul 12, 2019
Results first posted
Oct 28, 2020
Last update
Oct 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03302247
Responsible party
Sponsor
First posted
Oct 5, 2017
Start date
Jan 15, 2018
Primary completion
Mar 21, 2019
Completion
Jul 12, 2019
Results posted
Oct 28, 2020
Last update
Oct 28, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Gemcitabine

Start the discussion